$INKT
MiNK Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127033 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.163M
YoY Change -35.39%
% of Gross Profit
Research & Development $540.6K
YoY Change -84.23%
% of Gross Profit
Depreciation & Amortization $62.64K
YoY Change 25.28%
% of Gross Profit
Operating Expenses $540.6K
YoY Change -84.23%
Operating Profit -$1.885M
YoY Change -63.92%
Interest Expense $78.02K
YoY Change -29.07%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.807M
YoY Change -64.71%
Income Tax
% Of Pretax Income
Net Earnings -$1.807M
YoY Change -64.69%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$0.05
COMMON SHARES
Basic Shares Outstanding 39.55M 39.54M
Diluted Shares Outstanding 39.53M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.328M
YoY Change -1.12%
Cash & Equivalents $6.300M
Short-Term Investments
Other Short-Term Assets $11.20K
YoY Change -61.85%
Inventory
Prepaid Expenses $235.8K
Receivables
Other Receivables
Total Short-Term Assets $6.575M
YoY Change 1.62%
LONG-TERM ASSETS
Property, Plant & Equipment $799.5K
YoY Change -19.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $799.5K
YoY Change -19.36%
TOTAL ASSETS
Total Short-Term Assets $6.575M
Total Long-Term Assets $799.5K
Total Assets $7.375M
YoY Change -1.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.361M
YoY Change -44.84%
Accrued Expenses $2.645M
YoY Change -31.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.399M
YoY Change -28.82%
LONG-TERM LIABILITIES
Long-Term Debt $4.612M
YoY Change
Other Long-Term Liabilities $2.942K
YoY Change -95.4%
Total Long-Term Liabilities $2.942K
YoY Change -95.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.399M
Total Long-Term Liabilities $2.942K
Total Liabilities $7.402M
YoY Change -29.22%
SHAREHOLDERS EQUITY
Retained Earnings -$141.7M
YoY Change 10.79%
Common Stock $124.8M
YoY Change 8.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$17.55M
YoY Change
Total Liabilities & Shareholders Equity $7.375M
YoY Change -1.16%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.807M
YoY Change -64.69%
Depreciation, Depletion And Amortization $62.64K
YoY Change 25.28%
Cash From Operating Activities -$2.995M
YoY Change -28.86%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.810K
YoY Change
NET CHANGE
Cash From Operating Activities -2.995M
Cash From Investing Activities 0.000
Cash From Financing Activities 6.810K
Net Change In Cash -2.988M
YoY Change -29.36%
FREE CASH FLOW
Cash From Operating Activities -$2.995M
Capital Expenditures $0.00
Free Cash Flow -$2.995M
YoY Change -29.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001840229
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40908
dei Entity Registrant Name
EntityRegistrantName
MiNK Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2142067
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10010
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
994-8250
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
INKT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39549975
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6328239
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3367229
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
235786
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
53111
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11195
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
177964
CY2024Q3 us-gaap Assets Current
AssetsCurrent
6575220
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3598304
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
476741
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
495638
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
799522
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
953977
CY2024Q3 us-gaap Assets
Assets
7374742
CY2023Q4 us-gaap Assets
Assets
4552281
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2361175
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3911973
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2645494
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5037361
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2392324
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2453251
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7398993
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11402585
CY2024Q3 inkt Related Party Note
RelatedPartyNote
4611644
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2942
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
48072
CY2024Q3 inkt Due To Related Party
DueToRelatedParty
12915252
CY2023Q4 inkt Due To Related Party
DueToRelatedParty
11157073
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39549975
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34599119
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
395
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
346
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124836985
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
115772085
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-672838
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-430947
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141718631
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133396933
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-17554089
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-18055449
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7374742
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4552281
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
540638
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3427373
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4929993
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12179365
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1163033
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1796188
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3505260
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5241636
CY2024Q3 inkt Change In Fair Value Of Related Party Note
ChangeInFairValueOfRelatedPartyNote
180941
inkt Change In Fair Value Of Related Party Note
ChangeInFairValueOfRelatedPartyNote
350355
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1884612
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5223561
us-gaap Operating Income Loss
OperatingIncomeLoss
-8785608
us-gaap Operating Income Loss
OperatingIncomeLoss
-17421001
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
78015
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
107287
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
132995
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
421731
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
330915
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1806597
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5116266
us-gaap Net Income Loss
NetIncomeLoss
-8321698
us-gaap Net Income Loss
NetIncomeLoss
-16999262
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.5
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39533702
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39533702
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34497595
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34497595
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37115072
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37115072
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34293137
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34293137
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-61463
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
88623
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-241891
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20720
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1868060
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5027643
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8563589
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17019982
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-18055449
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3813295
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
45167
CY2024Q1 inkt Adjustment To Additional Paid In Capital Issuance Of Related Party Note
AdjustmentToAdditionalPaidInCapitalIssuanceOfRelatedPartyNote
792878
CY2024Q1 inkt Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
6896
CY2024Q1 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
697563
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
27033
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-20299207
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2701806
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-225595
CY2024Q2 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
818864
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
25313
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6288
CY2024Q2 inkt Sale Of Shares In Private Placement
SaleOfSharesInPrivatePlacement
5800000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-16576143
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1806597
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-61463
CY2024Q3 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
857812
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
25501
CY2024Q3 inkt Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
6801
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-17554089
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-401303
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5686041
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-81335
CY2023Q1 inkt Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
45496
CY2023Q1 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
887811
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
33328
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
346344
CY2023Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
379919
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4475781
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6196955
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28008
CY2023Q2 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
864918
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
33347
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22020
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
187377
CY2023Q2 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
97718
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-9495364
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5116266
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
88623
CY2023Q3 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
906150
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
33114
CY2023Q3 inkt Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
2950
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-13580793
us-gaap Profit Loss
ProfitLoss
-8321698
us-gaap Profit Loss
ProfitLoss
-16999262
us-gaap Depreciation
Depreciation
161568
us-gaap Depreciation
Depreciation
151045
us-gaap Share Based Compensation
ShareBasedCompensation
1420178
us-gaap Share Based Compensation
ShareBasedCompensation
2758668
us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
185352
inkt Gain On Forgiveness Of Liability
GainOnForgivenessOfLiability
1788204
inkt Gain On Forgiveness Of Liability
GainOnForgivenessOfLiability
266780
inkt Change In Fair Value Of Related Party Note
ChangeInFairValueOfRelatedPartyNote
350355
inkt Interest Accrued On Related Party Note
InterestAccruedOnRelatedPartyNote
54167
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
183167
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-256668
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1556563
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1544216
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
390524
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
760583
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1830383
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2156714
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7827809
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12726580
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73561
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73561
inkt Proceeds From Issuance Of Related Party Note
ProceedsFromIssuanceOfRelatedPartyNote
5000000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5800000
inkt Proceeds From Employee Stock Purchases And Option Exercises
ProceedsFromEmployeeStockPurchasesAndOptionExercises
19989
inkt Proceeds From Employee Stock Purchases And Option Exercises
ProceedsFromEmployeeStockPurchasesAndOptionExercises
70466
inkt Purchase Of Treasury Shares To Satisfy Tax Withholdings
PurchaseOfTreasurySharesToSatisfyTaxWithholdings
477637
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10819989
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-407171
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-31170
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-29559
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2961010
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13236871
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3367229
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19635725
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6328239
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6398854
us-gaap Interest Paid Net
InterestPaidNet
9027
us-gaap Interest Paid Net
InterestPaidNet
21439
inkt Issuance Of Stock Options For Payment Of Certain Employee Bonuses
IssuanceOfStockOptionsForPaymentOfCertainEmployeeBonuses
1031908
inkt Issuance Of Related Party Note
IssuanceOfRelatedPartyNote
792878
us-gaap Stock Issued1
StockIssued1
1011358
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141700000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6300000
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
910000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1831000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
398000
CY2024Q3 inkt Accrued Research Services Current
AccruedResearchServicesCurrent
613000
CY2023Q4 inkt Accrued Research Services Current
AccruedResearchServicesCurrent
302000
CY2024Q3 inkt Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
641000
CY2023Q4 inkt Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
2430000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
76000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2645000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5037000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6945716
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2140875
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.87
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
74230
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
52602
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
7234
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.27
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8952525
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1506311
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8952525
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M23D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1506311
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6274811
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M12D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1506311
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
789503
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
216314
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
221234
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.04
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
784583
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.15
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y10M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
74230
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
221234
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
883000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
939000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2452000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2759000
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(10) Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty and consumes both cash and management attention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127033-index-headers.html Edgar Link pending
0000950170-24-127033-index.html Edgar Link pending
0000950170-24-127033.txt Edgar Link pending
0000950170-24-127033-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inkt-20240930.htm Edgar Link pending
inkt-20240930.xsd Edgar Link pending
inkt-ex31_1.htm Edgar Link pending
inkt-ex31_2.htm Edgar Link pending
inkt-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
inkt-20240930_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable